Business
DECN Discusses Marketplace Intrique Surrounding Its Panacea Product Genultimate TBG, As It Readies June 6 Introduction
DECN Discusses Marketplace Intrique Surrounding Its Panacea Product Genultimate TBG, As It Readies June 6 Introduction.
About this update from Decision Diagnostics Corp
[{"type":"text","content":"Unsolicited Propositions Received For The Sale, Licensing Or Joint Venture Of Genultimate TBG, No Proposal Yet Acceptable But Improvement Seen LOS ANGELES, CA / ACCESSWIRE / May 29, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 17 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ('Sunshine') diabetes test strip, the internationally launched GenSure! ('Feather') diabetes test strip, and its GenChoice! ('Ladybug') test strip now under review for FDA 510K clearance. The company also markets the PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system, and the GenUltimate! Test 4Pets test strip and Avantage! meter launched earlier in 2019, and the panacea GenUltimate! TBG ('Dragonfly') highly precise diabetes testing system, ready for clinical trials.The company is pleased to announce that we have received three inquiries and propositions from three parties, two U.S. based and one internationally, for the wrapping of our new "TBG" technology into one of three types of transactions: Sale of the company or asset sale with valuation and bonus placed on our GenChoice and TBG technologies Exclusive license of the TBG technology inclusive all new uses/products that follow GenUltimate TBG A joint venture for the international rights to TBG, to be manufactured in Japan or by that party's Korean agentsKeith Berman, CEO of Decision Diagnostics comments, "We have spent a substantial amount of time digesting propositions for our GenUltimate TBG technology, and while we have favorable views of all three propositions, primarily because of the pedigree of the people behind the proposals, we are not yet ready to make a choice of a preferred type of transaction. At the moment the most promising of the propositions is the sale of an exclusive license to GenUltimate TBG, primarily because we can solve another issue we are wrestling with. We plan to discuss this other issue in the coming days. The company also expects to receive a fourth proposition from a well known international technology and manufacturing conglomerate that I have worked w...